RU2434865C2 - Аналоги тетрагидрохинолина в качестве мускариновых агонистов - Google Patents
Аналоги тетрагидрохинолина в качестве мускариновых агонистов Download PDFInfo
- Publication number
- RU2434865C2 RU2434865C2 RU2007127849/04A RU2007127849A RU2434865C2 RU 2434865 C2 RU2434865 C2 RU 2434865C2 RU 2007127849/04 A RU2007127849/04 A RU 2007127849/04A RU 2007127849 A RU2007127849 A RU 2007127849A RU 2434865 C2 RU2434865 C2 RU 2434865C2
- Authority
- RU
- Russia
- Prior art keywords
- group
- optionally substituted
- compound according
- halogen
- straight
- Prior art date
Links
- 239000000472 muscarinic agonist Substances 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims abstract 23
- 238000000034 method Methods 0.000 claims abstract 13
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims abstract 11
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims abstract 11
- 230000000694 effects Effects 0.000 claims abstract 5
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical group 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 108010009685 Cholinergic Receptors Proteins 0.000 claims 6
- 102000034337 acetylcholine receptors Human genes 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 6
- 230000008484 agonism Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000001118 alkylidene group Chemical group 0.000 claims 2
- 230000008485 antagonism Effects 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 230000004410 intraocular pressure Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 125000004844 (C1-C6) alkoxyimino group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000037821 progressive disease Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- -1 substituted Chemical class 0.000 claims 1
- 230000016776 visual perception Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000000147 tetrahydroquinolinyl group Chemical class N1(CCCC2=CC=CC=C12)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/019,556 US7550459B2 (en) | 2001-12-28 | 2004-12-21 | Tetrahydroquinoline analogues as muscarinic agonists |
| US11/019,556 | 2004-12-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007127849A RU2007127849A (ru) | 2009-01-27 |
| RU2434865C2 true RU2434865C2 (ru) | 2011-11-27 |
Family
ID=36123554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007127849/04A RU2434865C2 (ru) | 2004-12-21 | 2005-12-15 | Аналоги тетрагидрохинолина в качестве мускариновых агонистов |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7550459B2 (enExample) |
| EP (1) | EP1828176A1 (enExample) |
| JP (1) | JP5114208B2 (enExample) |
| KR (2) | KR101380794B1 (enExample) |
| CN (2) | CN101124222A (enExample) |
| AR (1) | AR052343A1 (enExample) |
| AU (1) | AU2005319426B2 (enExample) |
| BR (1) | BRPI0517485A (enExample) |
| CA (1) | CA2591766C (enExample) |
| IL (2) | IL184065A (enExample) |
| MX (1) | MX2007007588A (enExample) |
| NO (1) | NO20073183L (enExample) |
| NZ (1) | NZ555994A (enExample) |
| RU (1) | RU2434865C2 (enExample) |
| TW (2) | TWI433848B (enExample) |
| WO (1) | WO2006068904A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7550459B2 (en) * | 2001-12-28 | 2009-06-23 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
| EP1900732A4 (en) | 2005-06-24 | 2009-11-18 | Toyama Chemical Co Ltd | NEW NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF |
| US7678363B2 (en) * | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| EP1942879A1 (en) | 2005-10-31 | 2008-07-16 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| WO2007134136A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| AU2007292848A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| WO2009106534A1 (en) * | 2008-02-26 | 2009-09-03 | H. Lundbeck A/S | Novel heterocyclic carboxamides as m1 agonists |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| AU2012338581B2 (en) | 2011-11-18 | 2016-12-08 | Nxera Pharma Uk Limited | Muscarinic M1 receptor agonists |
| MX2015012043A (es) * | 2013-03-15 | 2016-03-17 | Acadia Pharm Inc | Agonistas muscarinicos. |
| CN103242230B (zh) * | 2013-05-02 | 2015-02-18 | 陕西步长高新制药有限公司 | 一种喹啉酮衍生物及其制备方法 |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| BR112022002698A2 (pt) | 2019-08-14 | 2022-07-19 | Incyte Corp | Compostos de imidazolil pirimidinilamina como inibidores de cdk2 |
| AU2020364007A1 (en) | 2019-10-11 | 2022-04-28 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| CN115073370B (zh) * | 2021-03-10 | 2024-12-17 | 成都硕德药业有限公司 | 新型烷基氨类化合物或盐、异构体、其制备方法及用途 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| EP4447953A1 (en) | 2021-12-13 | 2024-10-23 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0541263A1 (en) * | 1991-10-21 | 1993-05-12 | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. | 5-piperazinylalkyl-1,5-benzothiazepinones useful as calcium antagonists |
| EP0577325A1 (en) * | 1992-07-02 | 1994-01-05 | Sawai Pharmaceutical Co., Ltd. | Carbostyril derivatives and antiallergic agent |
| US5786367A (en) * | 1994-07-14 | 1998-07-28 | Otsuka Pharmaceutical Co., Ltd. | Cyclic amide derivatives |
| RU2158262C2 (ru) * | 1994-10-24 | 2000-10-27 | Эли Лилли Энд Компани | Производные 1,2,5-тиадиазола, промежуточные соединения, способы получения и фармацевтическая композиция |
| WO2001049679A1 (en) * | 1999-12-30 | 2001-07-12 | H. Lundbeck A/S | 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives |
| EP1260512A1 (en) * | 2000-02-29 | 2002-11-27 | Mitsubishi Pharma Corporation | Novel cyclic amide derivatives |
| WO2003057672A2 (en) * | 2001-12-28 | 2003-07-17 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
| US20040067931A1 (en) * | 2001-10-02 | 2004-04-08 | Kelly Nicholas Michael | Benzimidazolidinone derivatives as muscarinic agents |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3365457A (en) * | 1964-05-08 | 1968-01-23 | Sterling Drug Inc | N [(1-, 2-, 3-indolyl)-lower alkyl]-1, 5-iminocycloalkane and-1, 5-iminocycloalkene derivatives |
| US3324137A (en) * | 1964-05-08 | 1967-06-06 | Sterling Drug Inc | N-[indolyl-lower-alkanoyl]-1, 5-iminocycloalkanes and -iminocycloalkenes |
| US3364457A (en) * | 1966-05-13 | 1968-01-16 | Navy Usa | Electrical adapter |
| JPS63290821A (ja) | 1987-05-25 | 1988-11-28 | Otsuka Pharmaceut Co Ltd | 抗不整脈剤 |
| JP2886570B2 (ja) * | 1989-09-29 | 1999-04-26 | エーザイ株式会社 | 縮合ヘテロ環を有する化合物 |
| CA2050264A1 (en) * | 1990-08-30 | 1992-03-01 | Raymond Baker | Substituted pyrazine and its salts, compositions containing them and their use in medicine |
| US5149815A (en) * | 1991-04-29 | 1992-09-22 | American Home Products Corporation | N-substituted-2-aminoquinolines |
| US5093333A (en) * | 1991-04-29 | 1992-03-03 | American Home Products Corporation | N-substituted-2-aminoquinolines useful for treating hypofunction of the cholinergic system |
| JPH0673011A (ja) * | 1992-07-02 | 1994-03-15 | Sawai Seiyaku Kk | カルボスチリル誘導体および抗アレルギー剤 |
| DE4228095A1 (de) | 1992-08-24 | 1994-03-03 | Asta Medica Ag | Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung |
| IL110298A (en) * | 1993-07-13 | 1999-04-11 | Brann Mark Robert | Identification of ligands by selective amplification of cells transfected with receptors |
| JPH0881442A (ja) * | 1994-07-14 | 1996-03-26 | Otsuka Pharmaceut Co Ltd | 環状アミド誘導体 |
| US5510478A (en) * | 1994-11-30 | 1996-04-23 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
| US5468875A (en) * | 1994-12-22 | 1995-11-21 | American Home Products Corporation | 1-azabicycloheptane derivatives |
| EP0934932A4 (en) | 1996-08-22 | 2002-06-26 | Meiji Seika Kaisha | CHINOLINE DERIVATIVES AND PSYCHOTROPES MEDIUM |
| CA2326804C (en) | 1998-03-31 | 2006-05-02 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| EP1221443B1 (en) | 1999-10-13 | 2004-09-01 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazolidinone derivatives |
| CN1814596A (zh) | 2000-04-28 | 2006-08-09 | 阿卡蒂亚药品公司 | 毒蕈碱性激动剂 |
| WO2004089942A2 (en) * | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| US7550459B2 (en) | 2001-12-28 | 2009-06-23 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
| EP1613321A2 (en) | 2003-03-28 | 2006-01-11 | Acadia Pharmaceuticals Inc. | Muscarinic m1 receptor agonists for pain management |
-
2004
- 2004-12-21 US US11/019,556 patent/US7550459B2/en not_active Expired - Fee Related
-
2005
- 2005-12-15 AU AU2005319426A patent/AU2005319426B2/en not_active Ceased
- 2005-12-15 NZ NZ555994A patent/NZ555994A/en not_active IP Right Cessation
- 2005-12-15 CN CNA200580048487XA patent/CN101124222A/zh active Pending
- 2005-12-15 WO PCT/US2005/045313 patent/WO2006068904A1/en not_active Ceased
- 2005-12-15 EP EP05854098A patent/EP1828176A1/en not_active Withdrawn
- 2005-12-15 BR BRPI0517485-6A patent/BRPI0517485A/pt not_active IP Right Cessation
- 2005-12-15 JP JP2007548300A patent/JP5114208B2/ja not_active Expired - Fee Related
- 2005-12-15 RU RU2007127849/04A patent/RU2434865C2/ru not_active IP Right Cessation
- 2005-12-15 CN CN201210222989.1A patent/CN102796095B/zh not_active Expired - Fee Related
- 2005-12-15 KR KR1020077015954A patent/KR101380794B1/ko not_active Expired - Fee Related
- 2005-12-15 CA CA2591766A patent/CA2591766C/en not_active Expired - Fee Related
- 2005-12-15 KR KR1020137019680A patent/KR20130095846A/ko not_active Ceased
- 2005-12-15 MX MX2007007588A patent/MX2007007588A/es active IP Right Grant
- 2005-12-20 AR ARP050105365A patent/AR052343A1/es unknown
- 2005-12-20 TW TW094145345A patent/TWI433848B/zh active
- 2005-12-20 TW TW102131073A patent/TW201414731A/zh unknown
-
2007
- 2007-06-19 IL IL184065A patent/IL184065A/en not_active IP Right Cessation
- 2007-06-21 NO NO20073183A patent/NO20073183L/no not_active Application Discontinuation
-
2009
- 2009-05-27 US US12/473,220 patent/US8680115B2/en not_active Expired - Fee Related
-
2012
- 2012-05-21 IL IL219920A patent/IL219920A/en not_active IP Right Cessation
-
2014
- 2014-02-05 US US14/173,627 patent/US9522906B2/en not_active Expired - Fee Related
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0541263A1 (en) * | 1991-10-21 | 1993-05-12 | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. | 5-piperazinylalkyl-1,5-benzothiazepinones useful as calcium antagonists |
| EP0577325A1 (en) * | 1992-07-02 | 1994-01-05 | Sawai Pharmaceutical Co., Ltd. | Carbostyril derivatives and antiallergic agent |
| US5786367A (en) * | 1994-07-14 | 1998-07-28 | Otsuka Pharmaceutical Co., Ltd. | Cyclic amide derivatives |
| RU2158262C2 (ru) * | 1994-10-24 | 2000-10-27 | Эли Лилли Энд Компани | Производные 1,2,5-тиадиазола, промежуточные соединения, способы получения и фармацевтическая композиция |
| WO2001049679A1 (en) * | 1999-12-30 | 2001-07-12 | H. Lundbeck A/S | 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives |
| EP1260512A1 (en) * | 2000-02-29 | 2002-11-27 | Mitsubishi Pharma Corporation | Novel cyclic amide derivatives |
| US20040067931A1 (en) * | 2001-10-02 | 2004-04-08 | Kelly Nicholas Michael | Benzimidazolidinone derivatives as muscarinic agents |
| WO2003057672A2 (en) * | 2001-12-28 | 2003-07-17 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2434865C2 (ru) | Аналоги тетрагидрохинолина в качестве мускариновых агонистов | |
| KR101763674B1 (ko) | 핵 수용체에 결합하는 물질 | |
| MA31504B1 (fr) | Acides benzoylamino-indan-2-carboxyliques substitues et composes apparentes | |
| MA31373B1 (fr) | Composes amino-heterocycliques | |
| JP2008524328A5 (enExample) | ||
| Prisinzano et al. | Synthesis and determination of the absolute configuration of the enantiomers of modafinil | |
| RU2015147509A (ru) | Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы | |
| MA30821B1 (fr) | Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes | |
| MA30420B1 (fr) | Derives de terphenyle pour le traitment de la maladie d'alzheimer | |
| SE0104334D0 (sv) | Therapeutic agents | |
| MA29649B1 (fr) | Nouveaux derives de 2,4- dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk | |
| BRPI0612926B8 (pt) | compostos fluorados de 4-(2-amino-1-hidroxietila)fenol como agonistas de receptores b2 adrenérgicos, composição farmacêutica, combinação e uso de um composto | |
| BRPI0413533A (pt) | derivados de malonamida que bloqueiam a atividade de gama-secretase | |
| TW200736252A (en) | Novel heteroaryl substituted benzothiazoles | |
| MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
| TW200740760A (en) | Malonamide derivatives | |
| RU2008134702A (ru) | Способ лечения невропатической боли | |
| BR0313846A (pt) | Derivados de dioxano-2-alquilcarbamatos, sua preparação e sua aplicação em terapêutica | |
| US12258308B2 (en) | Benzene derivative | |
| MA31742B1 (fr) | Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique | |
| MA32290B1 (fr) | Nouvelle classe de spiro pipéridines pour le traitement de maladies neurodégénératives | |
| RU2010154417A (ru) | Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинетеразы, содержащая ее фармацетическая композиция, и ее применение в лечении когнитивных расстройств | |
| BRPI0518615A2 (pt) | derivados de malonamida | |
| RU2009103321A (ru) | Применение 2-бензоилимидазопиридинов в терапии | |
| RU2009103302A (ru) | Применение производных имидазо[1,2-а]пиридин-2-корбоксамидов в терапии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20171216 |